IDH1 and neoplasm: Inhibiting glycolysis through GLUT1/3, HK2, and HIF-1α blockade, modulating lipid metabolism via FASN and SREBP-1 inhibitors, and disrupting amino acid metabolism via glutaminase (GLS) and SLC7A11 inhibitors have shown promise in limiting tumor growth.483 Exploiting IDH1/2 mutations with 2-HG inhibitors reverses metabolic and epigenetic dysregulation,484 whereas combination therapies incorporating metabolic inhibitors with standard treatments block metabolic plasticity and enhance therapeutic responses.